Tracer library / [188Re]Re-RC-160
[188Re]Re-RC-160
Also written as Re-188-RC-160
- Radionuclide
- Re-188 t½ 1020 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- Somatostatin analog (octreotide-based peptide)
- Target / mechanism
- Somatostatin receptor targeting via octreotide PMID 8878464
- Clinical application
- Somatostatin-receptor-positive cancers (prostate adenocarcinoma, breast/mammary carcinoma, small cell lung carcinoma) treated by local/regional radiotherapy PMID 8567120
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [188Re]Re-RC-160, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 8878464: 'octreotide was directly labeled with 188Re by reducing disulfide bonds'. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article). Stage set/updated at stage 39 from PMID 8567120: 'The therapeutic potential of the somatostatin analogue RC-160 radiolabeled with 188Re was evaluated in nude mice bearing xenografts of human prostate adenocarcinoma.'.